Spots Global Cancer Trial Database for A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
Official Title: A Clinical Research of CD123-Targeted CAR-T in Myeloid Malignancies
Study ID: NCT02937103
Conditions
Interventions
Study Description
Brief Summary: The overall purpose of this study is to explore the therapeutic effect of CD123-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Myeloid Malignancies.
Detailed Description: Great progress has been made in the treatment of relapsed and refractory B cell malignancies with CD19-targeted CAR-T cells. However, for myeloid malignancies, which has higher morbidity, trials of CAR-T is few. CD123 is expressed on most myeloid leukemia cells so it is a ideal target for CAR-T. Some researches have revealed that CD123 is a marker of leukemia stem cells, which indicates that the eradication of CD123+ cells may prevent relapse of leukemia. This trial is designed and conducted to test the safety and effectiveness of CD123-targeted CAR-T.
Eligibility
Minimum Age: 14 Years
Eligible Ages: CHILD, ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Southwest Hospital of Third Millitary Medical University, Chongqing, Chongqing, China
Contact Details
Name: Cheng Qian, MD, PhD
Affiliation: Biotherapy Center of Southwest Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
